Skip to main content
Premium Trial:

Request an Annual Quote

William Blair Initiates Coverage of Exact Sciences

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair initiated coverage of Exact Sciences with an "Outperform" rating and "Aggressive growth" company profile.

Analyst Brian Weinstein rated the Madison, Wis.-based molecular diagnostics firm based on the "enormous" market opportunity that exists for its Cologuard stool-based DNA colorectal cancer screening test. He cited the need for an accurate, non-invasive test, as well as encouraging early data on the test's performance and management's experience running large pre-market approval trials as reasons for the positive outlook.

Exact Sciences is currently developing the test and expects to file for clearance from the US Food and Drug Administration in 2012. Weinstein predicted that clearance would come in 2013.

Last month, the company raised $64.7 million in a public offering to support clinical trials for the test and to carry out "strategic initiatives."

In late-October, Exact Sciences presented data from a validation study for Cologuard. Weinstein said that though the firm has no other test in the pipeline or for sale, and any problems with the clinical study of Cologuard or its commercialization would be "a major issue, we believe this name offers significant value to investors patient enough to be rewarded, owing to the differentiated product and immense market opportunity."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.